Jiangsu Kanion Pharmaceutical Co. Ltd. Class ASSE: 600557

Announcement on Receiving the Clinical Trial Approval Notice for Qingshen Tongluo Granules

· Issued by Jiangsu Kanion Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Receiving the Clinical Trial Approval Notice for Qingshen Tongluo Granules

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis